Context Therapeutics Announces Chief Medical Officer Transition

By Dr. Matthew Watson

Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer

See the rest here:
Context Therapeutics Announces Chief Medical Officer Transition

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - May 6th, 2025
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - May 6th, 2025
uniQure to Announce First Quarter 2025 Financial Results - May 6th, 2025
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights - May 6th, 2025
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 - May 6th, 2025
FibroGen to Report First Quarter 2025 Financial Results - May 6th, 2025
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates - May 6th, 2025
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates - May 6th, 2025
Certara Reports First Quarter 2025 Financial Results - May 6th, 2025
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - May 6th, 2025
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - May 6th, 2025
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET - May 6th, 2025
Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of... - May 6th, 2025
Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company - May 6th, 2025
Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with... - May 6th, 2025
argenx to Present at BofA Securities 2025 Health Care Conference - May 6th, 2025
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity - May 6th, 2025
Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy - May 6th, 2025
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation - May 6th, 2025
Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa - April 23rd, 2025
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala - April 23rd, 2025
Cambridge’s DIOSynVax and Singapore’s ACM Biolabs to Advance Pandemic-Ready Universal Bird Flu Vaccine with International Support - April 23rd, 2025
NewGen Filed 2024 Annual Report on Form 20-F - April 23rd, 2025
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs - April 23rd, 2025
Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm - April 23rd, 2025
Elite Clinical Network and HealthyU Clinics Announce Strategic Partnership to Expand Access to Clinical Research - April 23rd, 2025
Andrew Taylor joins Novonesis’ Executive Leadership Team - April 23rd, 2025
Sirona Biochem Announces Debenture Financing - April 23rd, 2025
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors - April 23rd, 2025
Digicann Ventures Provides Update Regarding Proposed RTO Transaction - April 23rd, 2025
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe... - April 23rd, 2025
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones - April 23rd, 2025
Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 - April 23rd, 2025
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates - April 23rd, 2025
NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into... - April 23rd, 2025
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and... - April 23rd, 2025
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS) - April 23rd, 2025
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - April 23rd, 2025
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a... - April 23rd, 2025
Preliminary Results for the Year Ended 31 December 2024 - April 14th, 2025
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects - April 14th, 2025
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements - April 14th, 2025
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - April 14th, 2025
Scilex Holding Company Announces 1-for-35 Reverse Stock Split - April 14th, 2025
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments - April 14th, 2025
TestoPrime Reviews: Best Testosterone Booster Supplement For Men Over 40 & 50 – Is TestoPrime Tablets Safe? - April 14th, 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 14th, 2025
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and... - April 14th, 2025
argenx Announces Annual General Meeting of Shareholders on May 27, 2025 - April 14th, 2025
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 14th, 2025
Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High... - April 14th, 2025
4DMT Announces New Employment Inducement Grants - April 14th, 2025
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements - April 14th, 2025
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - April 14th, 2025
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 14th, 2025
Kane Biotech Announces New Agreement with Outside the Box Capital Inc. - April 14th, 2025
Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the... - April 14th, 2025
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy - April 14th, 2025
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US - April 14th, 2025
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - March 31st, 2025
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results - March 31st, 2025
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - March 31st, 2025
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors - March 31st, 2025
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX - March 31st, 2025
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - March 31st, 2025
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress - March 31st, 2025
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates - March 31st, 2025
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension... - March 31st, 2025
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery... - March 31st, 2025
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 - March 31st, 2025
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - March 31st, 2025
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - March 31st, 2025
First Three Children to Commence Treatment With Ryoncil® - March 31st, 2025
BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office - March 31st, 2025
Opthea Announces Decision to Discontinue Wet AMD Trials - March 31st, 2025
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the... - March 31st, 2025
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA - March 31st, 2025
AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances - March 31st, 2025
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - March 31st, 2025
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - March 22nd, 2025

Global News Feed commento

Comments Off | data

May 6th, 2025

About... Dr. Matthew Watson

This author published 6192 posts in this site.

Comments are closed.

Previous post - Next post

Context Therapeutics Announces Chief Medical Officer Transition

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites